CN102010512B - Preparation method and application of water-soluble chitosan micro-particles - Google Patents
Preparation method and application of water-soluble chitosan micro-particles Download PDFInfo
- Publication number
- CN102010512B CN102010512B CN2010105058496A CN201010505849A CN102010512B CN 102010512 B CN102010512 B CN 102010512B CN 2010105058496 A CN2010105058496 A CN 2010105058496A CN 201010505849 A CN201010505849 A CN 201010505849A CN 102010512 B CN102010512 B CN 102010512B
- Authority
- CN
- China
- Prior art keywords
- water
- soluble chitosan
- wsc
- preparation
- fat
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Active
Links
Landscapes
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Medicinal Preparation (AREA)
Abstract
The invention discloses a preparation method and application of water-soluble chitosan micro-particles. The water-soluble chitosan micro-particles comprise water-soluble chitosan micro-spheres and water-soluble chitosan nano-particles. The invention provides the application of the water-soluble chitosan micro-particles in preparing weight-loss or lipid lowering medicaments or foods. It is summarized through researches that when applied to the preparation of medicaments or foods for inhibiting appetite or reducing internal fat, the water-soluble chitosan micro-particles have a good effect. The invention provides a technical support for better applying water-soluble chitosan to the preparation of the foods or the medicaments for losing weight, realizing effective reduction of food feeding quantity or administration dosage, and obtaining a good weight-losing effect.
Description
Technical field
The invention belongs to medicine and functional food technical field, be specifically related to a kind of preparation and application thereof of water-soluble chitosan microgranule.
Background technology
Chitosan (CTS) is to make through the chitin deacetylase base, is a kind of natural cation polysaccharide, is present in a large number in the carapace of ocean arthropod (shrimp, Eriocheir sinensis etc.), also is present in lower animal mushroom, insecticide, the alga cells film, and resource is very abundant.Chitosan itself has positive charge can combine it with fat that has negative charge and bile acid etc.; Chitosan can also through hydrophobic bond and neutral fat combine to come emulsifying they.A large amount of animal and human's body result of the test proof chitosans can obviously reduce cholesterol and fat content in the blood.
Even at present most researchers think chitosan as a kind of dietary fiber and food additive to the almost non-toxic side effect of human body, still may cause constipation, stomachache, vomiting, untoward reaction such as nauseating but many reports show a large amount of edible chitosans.So, need to seek a kind of feasible method and solve chitosan dosage and side-effect problem in use.Because common chitosan can only be dissolved in the weakly acidic solution; Can not be soluble in water; Cause chitosan low, need the long period in human body, to dissolve the effect of competence exertion Weight-reducing and lipid-lowering afterwards, bring inconvenience for taking of chitosan the joint efficiency of fat and cholate.
Simultaneously, in the prior art, chitosan all is wall material or the adjuvant as preparation other drug microgranule usually, adopts water to add the preparation of oil phase emulsification method, because emulsion polymerization method prepares and used a large amount of initiators and organic solvent in the process, can introduce toxicity.
Water-soluble chitosan (WSC) is the derivant of chitosan, and it can be well soluble in water, demonstrated the advantageous property that common chitosan does not have.A lot of at present researchs show that the common chitosan of ability force rate of water-soluble chitosan cholesterol reducing and absorbing fats is stronger.The applicant discloses chitosan, water-soluble chitosan microsphere and nanoparticle in number of patent application is 200910214313.6 and 200910214314.0 patent application, adopt direct preparation method to prepare, and its application aspect blood fat reducing is provided.But; 200910214313.6 the research that provides with 200910214314.0 patent application based on be hyperlipidemia animal model rather than fat model; According to art technology general knowledge; Hyperlipidemia model and fat model are all existing significant difference aspect the physiology and the mechanism of action; Though the experimental summary that the above-mentioned technical research achievement of the applicant successfully is applied to the blood fat reducing model through chitosan and water-soluble chitosan microgranule obtains the blood lipid level that chitosan and water-soluble chitosan microgranule can well reduce hyperlipidemia rats; Can be applicable to prepare fat-reducing medicament or food aspect, whether can not be applied to prepare and have the medicine that reduces body weight or the effect of food aspect but relate to it.Along with the continuous quickening of present rhythm of life, reduce body weight or fat-reducing and belong to a special and technical research field independently, demand is extremely urgent.
Simultaneously; Existing result of study has shown that all the particle diameter of water-soluble chitosan is when diminishing; Because the rapid increase of surface area is absorbing fats and fatty acid more; Finally can better reduce cholesterol and fat in the blood, result of study shows that particle diameter is more little, and the water-soluble chitosan action effect is good more.
Summary of the invention
The objective of the invention is to overcome the deficiency of existing water-soluble chitosan microgranule application technology, provide a kind of water-soluble chitosan microgranule new application, said water-soluble chitosan microgranule comprises water-soluble chitosan microsphere and water-soluble chitosan nanoparticle.The invention provides said water-soluble chitosan microsphere and nanoparticle new application technology scheme aspect preparation fat-reducing or auxiliary antilipemic food or medicine.
The present invention adopts spray drying method for preparation water-soluble chitosan microsphere.With water-soluble chitosan with deionized water dissolving, be placed to the laggard capable spray drying of no bubble, promptly get the water-soluble chitosan microsphere.The drying process with atomizing condition: inlet temperature is 140～190 ℃, and outlet temperature is 80～100 ℃, and peristaltic pump speed is 300～1000ml/h, compressed air pressure 100～150kPa, nozzle diameter 0.7mm.
Said water-soluble chitosan nanoparticle is that the method that adopts ionomer, spray drying method to combine prepares.It is an amount of to take by weighing water-soluble chitosan, is mixed with certain quality concentration with deionized water dissolving; It is an amount of that other gets sodium polyphosphate, is dissolved in the deionized water of certain volume; Under continuous stirring condition, slowly drip the polyphosphoric acids sodium solution in water-soluble chitosan solution, until blue opalescence occurring, promptly get the suspension of water-soluble chitosan nanoparticle; This suspension rotary evaporation is concentrated the back adopt spray drying method to volatilize solvent, obtain the solid of water-soluble chitosan nanoparticle.The drying process with atomizing condition: inlet temperature is 140～180 ℃, and outlet temperature is 80～100 ℃, and peristaltic pump speed is 300～1000ml/h, compressed air pressure 100～150kPa, nozzle diameter 0.5mm.
It is under 60～80 ℃ of temperature control conditions, to carry out that evaporation and concentration is revolved in above-mentioned commentaries on classics, nanometer suspension liquid is evaporated to volume is reduced to original half the getting final product.
Prior art comprises that number of patent application is 200910214313.6 patent application; The water-soluble chitosan raw material is not carried out more deep research; Sum up with analyzing through long-term a large amount of experimentation; The factor that influences water-soluble chitosan fat-reducing effect not only has relation with the particle diameter of water-soluble chitosan, and more deacetylation and the molecular weight with water-soluble chitosan has direct relation.
The present invention is through long-term lot of experiments, and summary obtains: the water-soluble chitosan deacetylation has certain antiobesity action with molecular weight 1～3,000,000 60%～99%.Can realize better that the technical scheme of the object of the invention is: in the application of water-soluble chitosan microgranule of the present invention aspect preparation slimming medicine or food; Raw material is optimized, preferably adopt the deacetylation scope be 85%～99% and molecular weight be that 10～500,000 water-soluble chitosan prepares the water-soluble chitosan microgranule.
The application of water-soluble chitosan provided by the invention aspect preparation fat-reducing or fat-reducing medicament or food; Specifically aspect the medicine or food applications of preparation fat-reducing; The water-soluble chitosan microsphere (WSC-MP) and the water-soluble chitosan nanoparticle (WSC-NP) that can adopt the present invention to prepare, preferred WSC-MP.
Aspect the medicine or food of preparation appetite-suppressing, the water-soluble chitosan microsphere (WSC-MP) and the water-soluble chitosan nanoparticle (WSC-NP) that can adopt the present invention to prepare, preferred WSC-MP.
Aspect preparation minimizing body fat medicine or food applications, the water-soluble chitosan microsphere (WSC-MP) and the water-soluble chitosan nanoparticle (WSC-NP) that can adopt the present invention to prepare, preferred WSC-MP.
The invention has the beneficial effects as follows:
The present invention constantly attempts water-soluble chitosan be applied to the to lose weight technique effect in field and sum up, but a large amount of experiment shows that effect is indeterminate also unstable when constantly summing up the application technology effect of water-soluble chitosan aspect blood fat reducing.The present invention has at first carried out systematic research to the deacetylation of raw material one water-soluble chitosan of preparation water-soluble chitosan microgranule and the influence of molecular weight; Draw the raw material scheme that can obtain stable significantly fat-reducing and lipid-lowering effect, the technical scheme that provides the preparation aspect more to optimize pointedly to existing water-soluble chitosan;
The more important thing is; According to art technology general knowledge, the water-soluble chitosan diameter of particle is more little usually, and specific surface area also increases greatly; Help absorbing fats and fatty acid more; Finally can better reduce intravital cholesterol and fat, but the practical application effect data are also unstable and can have regularity, this brings huge obstruction for applying of water-soluble chitosan.The present invention has studied the important factor in order of water-soluble chitosan microgranule in the fat-reducing application facet; Summary obtains different-grain diameter and changes the influence to the water-soluble chitosan effect; Prove through lot of experiments; Overcome the difficulty of modeling, obtain, in important fat-reducing application through creationary analysis and experimental summary; Comprise the medicine or the food aspect of preparation appetite-suppressing, fat-reducing, minimizing body fat, the effect of water-soluble chitosan microsphere all is superior to the water-soluble chitosan nanoparticle.The present invention has overcome the prejudice of technological thinking set and prior art, for better developing water-soluble chitosan technical foundation and support is provided.Thus, the invention provides water-soluble chitosan in food or the new application scheme of medicine of preparation aspect the fat-reducing.
The specific embodiment.
Below in conjunction with specific embodiment further explain the present invention.Employed test method is conventional method like no specified otherwise among the following embodiment; Employed material, reagent etc. like no specified otherwise, are the reagent and the material that can obtain from commercial sources.
The preparation of embodiment 1 water-soluble chitosan microsphere
Take by weighing 27.2g water-soluble chitosan (according to existing method self-control or commercial product, molecular weight is 10～300,000, and deacetylation is 85%～99%) and be added to mechanical agitator stirring in the 1800ml deionized water, be placed to the laggard capable spray drying of no bubble; Use homemade L-117 type laboratory with spray dryer (the next prosperous science and trade in Beijing Co., Ltd; Also can adopt other producer's similar devices) preparation micron grain; The preparation process is used the nozzle of standard 0.7mm; 160 ℃ of drying tower EATs, 80～85 ℃ of outlet temperatures, hot air flow 90% (about 35m
3/ h), peristaltic pump flow 50% (about 600ml/h), compressed air pressure 120kPa.Method for preparing also can be 200910214313.6 preparation scheme with reference to the applicant at number of patent application.
Prepare 16.6g water-soluble chitosan microsphere, productive rate is 61.2%.Use laser particle analyzer (Britain also can adopt other producer's similar devices for Zetasizer 3000HAS, Ma Erwen instrument company) that its particle diameter is measured, mean diameter is 2 μ m.
The preparation of embodiment 2 water-soluble chitosan microspheres
Get 28g water-soluble chitosan (according to existing method self-control or commercial product, molecular weight is 20～300,000, and deacetylation is 80%～85%) and be added to mechanical agitator stirring in the 1800ml deionized water; After being placed to no bubble; Spray drying method for preparation micron grain, the preparation process is used the nozzle of standard 0.7mm, 190 ℃ of drying tower EATs; 85～90 ℃ of outlet temperatures, hot air flow 90% (about 35m
3/ h), peristaltic pump flow 500ml/h, compressed air pressure 100kPa.
Prepare 17.4g water-soluble chitosan microsphere, productive rate is 62.3%.Use laser particle analyzer that its particle diameter is measured, mean diameter is 1.58 μ m.
The preparation of embodiment 3 water-soluble chitosan microspheres
Get 27.2g water-soluble chitosan (according to existing method self-control or commercial product, molecular weight is 40～500,000, deacetylation 60%～80%), other experimental techniques are with embodiment 1.
Prepare 16.9g water-soluble chitosan microsphere, productive rate is 62.1%.Use laser particle analyzer that its particle diameter is measured, mean diameter is 1.32 μ m.
The preparation of embodiment 4 water-soluble chitosan nanoparticles
Take by weighing water-soluble chitosan (molecular weight is 10～500,000, deacetylation be 85%～99%) 25g, use the 10000ml deionized water dissolving; Other gets sodium polyphosphate 2.5g, is dissolved in the 2500ml deionized water; Under continuous stirring condition, slowly drip the polyphosphoric acids sodium solution in water-soluble chitosan solution, until blue opalescence occurring, promptly get the suspension of water-soluble chitosan nanoparticle; This suspension rotary evaporation is concentrated the back volatilize solvent with spray drying method, obtain the solid of water-soluble chitosan nanoparticle, said rotary evaporation concentrates with reference to conventional method, is concentrated into volume and reduces about 1/2.
Said drying process with atomizing condition: inlet temperature is 140 ℃, and outlet temperature is 85 ℃, and peristaltic pump speed is 600ml/h, compressed air pressure 120kPa, nozzle diameter 0.5mm.
Prepare 17.9g water-soluble chitosan nanoparticle, productive rate is 65%.Use laser particle analyzer that its particle diameter is measured, mean diameter is 500～1000nm.
The preparation of embodiment 5 water-soluble chitosan nanoparticles
Take by weighing water-soluble chitosan (molecular weight is 20～500,000, deacetylation be 85%～99%) 30g, use the 10000ml deionized water dissolving; Other gets sodium polyphosphate 3g, is dissolved in the 3000ml deionized water; Under continuous stirring condition, slowly drip the polyphosphoric acids sodium solution in water-soluble chitosan solution, until blue opalescence occurring, promptly get the suspension of water-soluble chitosan nanoparticle; This suspension rotary evaporation is concentrated the back volatilize solvent with spray drying method, obtain the solid of water-soluble chitosan nanoparticle, said rotary evaporation concentrates with reference to conventional method, is concentrated into volume and reduces about 1/2.
Said drying process with atomizing condition: inlet temperature is 180 ℃, and outlet temperature is 85 ℃, and peristaltic pump speed is 400ml/h, compressed air pressure 150kPa, nozzle diameter 0.5mm.
Prepare 21.9g water-soluble chitosan nanoparticle, productive rate is 66.4%.Use laser particle analyzer that its particle diameter is measured, mean diameter is 800～1000nm.
The preparation of embodiment 6 water-soluble chitosan nanoparticles
Adopt that molecular weight is 50,000, deacetylation is 70% water-soluble chitosan, other experiment conditions are with embodiment 5.
Prepare the 15.8g chitosan nano, productive rate is 48%.Use laser particle analyzer that its particle diameter is measured, mean diameter is 500nm.
Embodiment 7 application experiments
(1) test material
Present embodiment with deacetylation be 85～99% and molecular weight be that 10～500,000 water-soluble chitosan is a raw material, prepare water-soluble chitosan microsphere and water-soluble chitosan nanoparticle as the application experiment material according to the method for the invention.
The high lipid food prescription: normal feedstuff (commercial) 80%, yolk powder (commercial) 10%, Adeps Sus domestica (commercial) 10% is mass percent.
Normal saline.
Use 90 of male SD rats, body weight 200 ± 20g (purchasing Experimental Animal Center) in the experiment in Guangdong Province.Raising in temperature and humidity keeps constant room, free diet.
(2) experimentation
The rat adaptability was raised after 7 days, was divided into 9 groups (n=10) at random: dosage (M-WSC-NP), water-soluble chitosan nanoparticle treatment group low dose of (L-WSC-NP) in dosage (M-WSC-MP), water-soluble chitosan microsphere treatment group low dose of (L-WSC-MP), water-soluble chitosan nanoparticle treatment group heavy dose of (H-WSC-NP), the water-soluble chitosan nanoparticle treatment group in normal physiological saline control group (NF), high lipoprotein emulsion matched group (HF), water-soluble chitosan matched group (WSC), water-soluble chitosan microsphere treatment group heavy dose of (H-WSC-MP), the water-soluble chitosan microsphere treatment group.
Weekly the mice body weight is weighed twice and record in the experimentation; Every rat of every day record give appetite, surplus appetite, berley amount.The edible common commercially available rat feed of NF group finishes up to experiment, and the edible high lipid food of HF group finishes up to experiment; In other group every day in edible 4 weeks of high lipid food, the WSC matched group is irritated stomach respectively every day and is accepted the 250mg/kg water-soluble chitosan in 4 weeks subsequently; H-WSC-MP group is irritated stomach respectively with the H-WSC-NP group and accept 500mg/kg water-soluble chitosan microsphere and nanoparticle every day, and M-WSC-MP group and M-WSC-NP organize and irritate stomach every day and accept 250mg/kg water-soluble chitosan microsphere and nanoparticle; L-WSC-MP group and L-WSC-NP organize and irritate stomach every day and accept 125mg/kg water-soluble chitosan microsphere and nanoparticle.The equal free diet of all group rats does not add control.
After experiment finishes, the equal fasting of all rats one day.Behind the etherization, the capillary tube eye socket is got blood system and is loaded on common centrifuge tube and anticoagulant centrifuge tube.All rats are all dissected subsequently, get perirenal fat, testis week fat and weighing.
Get not the blood handled through anticoagulant under the 3000r/min condition centrifugal 15 minutes; Get top serum with test kit at automatic biochemical analyzer (AMS-18; Beijing Ao Pusen technology & development Co.; China also can adopt other producer's similar devices) last T-CHOL (TC), triglyceride (TG), high density lipoprotein (HDL-C), the low density lipoprotein, LDL of measuring in the serum (LDL-C).
The blood that the anticoagulant of learning from else's experience is handled is surveyed its viscosity with WBV analyzer (China also can adopt other producer's similar devices for LBY-N6B, Pulisheng Instruments Co., Ltd., Beijing).
(3) toxicity test
200 of the NIH mices of cleaning level, body weight is between 18～22g, and health status is good, and male and female half and half are provided by Guangdong Medical Lab Animal Center.The laboratory animal certification of fitness: SCXK (Guangdong) 2008-0002.The experiment mice male and female are divided cage, and the foot food is fed, freely drink water, and 18 ℃～22 ℃ of room temperatures, the laboratory relative humidity is 55～70%.
According to the character of being tried thing and given data, the dosage of general many employings 0.1,1.0 and 10.0g/kgBW, each is with 2～3 animal preruns.According to death condition in the 24h, estimate LD
50The possible range of (adopting engler's algoscopy suddenly) is confirmed the dosage of formal test.Also can adopt a dosage simply,,, observe the poisoning manifestations of animal in the 2h with 5 animal preruns like 215mg/kgBW.Like serious symptom, estimate that most animals maybe be dead, can adopt the dosage series that is lower than 215mg/kgBW, otherwise symptom is lighter, then can adopt the dosage series that is higher than this dosage.This experiment adopts the 10.0g/kgBW dosage condition of carrying out to grope.Give mouse stomach 10% (g/100mL) WSC-MP and WSC-NP suspension.Final definite dosage range is at 1.0～10.0g/kgBW.
60 of NIH kind mices are got in formal test, and male and female half and half are divided into 3 groups at random, WSC group, WSC-MP group, WSC-NP group, 20 every group, male and female half and half.Every group by 1000,2150,4640,4 dosage of 10000mg/kg carry out administration, each dosage uses 5 experiment mices.
More than the preceding fasting 12h of experiment; With WSC, WSC-MP, 3 sample suspensions of WSC-NP; Each sample respectively by 1000,2150,4640,4 dosage of 10000mg/kg BW carry out gastric infusion; Cmax is 100mg/mL (through irritating the stomach syringe needle, not causing the concentration that former pharmacology voltinism shape changes just), and maximum volume is 0.8mL/20mg.The experiment back is observed the death condition that is produced in the 7d continuously.Notice whether mice spirit, activity, diet abnormal conditions occur in the 7d after receiving the reagent thing.For the mice of death the anatomic observation heart, liver, spleen, lung, kidney etc. immediately, record pathological changes situation.Observe following index in the experimentation simultaneously:
Breathe and cardiovascular: comprise that rapid breathing or slow, nose secrete with excessivelying, it is fast etc. to touch the pareordia heart rate;
Genitourinary system: comprise labia, mammary gland swelling, perineal position dirt etc.;
Skin and hair color: comprise color, integrity, have not congested, cyanosis is pale, dermexanthesis, fur are loose etc.;
Eyes: blepharoptosis, exophthalmos, tremble etc.; Comprising that pupil has does not dwindle or amplifies, and the stream birth, sheds tears etc.
Select 60 of the healthy cleaning level of body weight 18～22g NIH kind mices for use, be divided into 3 groups at random, promptly WSC organizes, WSC-MP organizes, the WSC-NP group, every group of 20 mices, male and female half and half.Fasting is 12 hours before the administration.WSC, WSC-MP, a WSC-NP3 sample suspension; Dosage by 10000mg/kgBW is irritated stomach, and every separated 4h irritates stomach 1 time, carries out altogether 3 times; Free diet after the administration; Observe 7d then continuously, whether the record mice spirit, activity, diet abnormal conditions occur in the 7d after receiving the reagent thing, and the death condition of mice respectively organized in record.For the mice of death the anatomic observation heart, liver, spleen, lung, kidney etc. immediately, record pathological changes situation.
(4) interpretation
1, table 1 is seen in the influence of experimental rat body weight:
Table 1WSC-MP and WSC-NP to the influence of obese rat weight gain (means+SE, n=10)
Annotate: have significant difference (p＜0.05) in the same column data between different letter representation data
Can find out by table 1, compare that the weight gain of high fat group and other all treatment groups all is significantly higher than normal group after the modeling, shows that the fat model of experimental rat is successfully set up with the normal group weight gain.After giving the corresponding treatment medicine respectively, compare with high fat matched group with the normal control group, each organizes the effect that all shows obvious inhibition body weight gain each group of WSC-MP and WSC-NP, and with dosage obvious dependency is arranged, promptly along with dosage increase effect is obvious more.But, see in the whole experiment that the antiobesity action of WSC-MP is better than each treatment group of WSC-NP.So weight data shows all body weight gains of ability good restraining obese rat of WSC-MP and WSC-NP, the effect of fat-reducing is arranged, and the antiobesity action of WSC-MP is better than WSC-NP.
2, the food utilization of experimental rat is seen table 2:
Table 2WSC-MP and WSC-NP to the influence of obese rat food utilization (means+SE, n=10)
Annotate: have significant difference (p＜0.05) in the same column data between different letter representation data
Table 2 is rat food utilization correlation circumstances, therefrom can find out with normal group, high fat group and compare, and except that L-WSC-NP and M-WSC-NP group, the other treatment group all has the effect of inhibition experimental rat appetite in various degree.This shows, all dosage of WSC-MP and the high dose of WSC-NP all have the effect that suppresses obese rat appetite, and this also is the one of the main reasons that rat body weight reduces that causes fat.And when therapeutic dose increased, it is remarkable that this effect is tending towards.But all in all the inhibitory action of WSC-NP is less than WSC-MP.
3, the fat body ratio of experimental rat is seen table 3:
Table 3WSC-MP and WSC-NP to the influence of obese rat fat body ratio (means+SE, n=10)
Annotate: have significant difference (p＜0.05) in the same column data between different letter representation data
Can find out that by table 3 the fat body of high fat group shows that than apparently higher than other groups all treatment groups all have the effect of good minimizing obese rat body fat.But, between the various dose group of different therapeutants and no significant difference.Experimental result shows that the effect of WSC-MP treatment group is apparently higher than corresponding WSC-NP.So WSC-MP and WSC-NP all have the effect that reduces the obese rat body fat, and the WSC-MP effect is superior to WSC-NP.
4, the serum biochemistry index of experimental rat is seen table 4:
Table 4WSC-MP and WSC-NP to obese rat serum biochemistry index influence (means+SE, n=10)
Annotate: have significant difference (p＜0.05) in the same column data between different letter representation data
TC data show in the table 4: with high fat matched group significant difference is arranged more all, explain that all treatment groups all have the effect that reduces blood fat in the obese rat body; And the light water soluble chitosan reduces the effect of TC apparently higher than WSC-MP and all dose groups of WSC-NP.The TG data also demonstrate, and compare with the normal control group, and the light water soluble chitosan possesses good reduction TG effect.But the data of HDL find that but used treatment group all can reduce the intravital HDL level of obese rat.
The LDL data show that all treatment groups all have the effect of LDL level in the good reduction obese rat body, and the effect of light water soluble chitosan is the most obvious; The effect of WSC-MP and each dose groups of WSC-NP all has obvious dosage correlation, i.e. dosage increase effect strengthens.And, when heavy dose, possess the effect of the reduction LDL suitable with the light water soluble chitosan.So WSC, WSC-MP and WSC-NP all can improve the level of obese rat blood fat lipid to a certain extent, possesses the auxiliary effect that reduces the obese rat blood fat.
5, the WBV of experimental rat is seen table 5:
Table 5WSC-MP and WSC-NP to the obese rat WBV influence (means+SE, n=10)
Annotate: have significant difference (p＜0.05) in the same column data between different letter representation data
Can find out that by table 5 WSC, WSC-MP and WSC-NP compare with high fat matched group and no significant difference with normal group the WBV influence of obese rat.Show that these therapeutants possibly not have well to reduce the effect of obese rat WBV.
6, toxicity test result
The mortality rate of WSC does not reach half the lethal dose, so the LD of WSC
50Should be greater than 10000mg/kg.And the WSC-NP mortality rate is 65%, table look-up LD
50=2370mg/kg.The mortality rate of WSC-MP is 55%, table look-up LD
50=4080mg/kg.Toxicity result shows that WSC is actual innocuous substance, and WSC-MP and WSC-NP are low toxicity material.
This experimental result shows; All growths of the body weight of ability good restraining obese rat of WSC, WSC-MP and WSC-NP in experimentation all around; Each treatment group effect of WSC-MP is superior to the antiobesity action of each treatment group of WSC-NP, and the inhibitory action of the middle high dose group of WSC-MP and WSC-NP and WSC is suitable.Observation through to food utilization in the experimentation finds that except that M-WSC-NP and L-WSC-NP group, the reason that the other treatment group of WSC, WSC-MP and WSC-NP suppresses the obese rat body weight gain is the appetite that has suppressed obese rat.Body fat data show that WSC-MP and WSC-NP all have the effect that reduces the obese rat body fat, and the WSC-MP effect is superior to WSC-NP.Blood fat biochemical indicator data show that WSC, WSC-MP and WSC-NP possess the effect of auxiliary antilipemic.
Claims (4)
1. the application of a water-soluble chitosan microgranule is characterized in that being applied to prepare the medicine or the food aspect of appetite-suppressing; Said water-soluble chitosan microgranule is that water-soluble chitosan is water-soluble, adopts spray drying method for preparation to obtain; Said water-soluble chitosan deacetylation scope be 60%～99% and molecular weight be 1～3,000,000.
2. according to the application of the said water-soluble chitosan microgranule of claim 1, it is characterized in that said water-soluble chitosan deacetylation scope be 85%～99% and molecular weight be 10～500,000.
3. the application of a water-soluble chitosan microgranule is characterized in that being applied to prepare the medicine or the food aspect of appetite-suppressing; Said water-soluble chitosan microgranule is with polyphosphoric acids sodium solution and water-soluble chitosan solution generation ionomer after spray drying method for preparation obtains; Said water-soluble chitosan deacetylation scope be 60%～99% and molecular weight be 1～3,000,000.
4. according to the application of the said water-soluble chitosan microgranule of claim 3, it is characterized in that said water-soluble chitosan deacetylation scope be 85%～99% and molecular weight be 10～500,000.
Priority Applications (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN2010105058496A CN102010512B (en) | 2010-10-12 | 2010-10-12 | Preparation method and application of water-soluble chitosan micro-particles |
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN2010105058496A CN102010512B (en) | 2010-10-12 | 2010-10-12 | Preparation method and application of water-soluble chitosan micro-particles |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| CN102010512A CN102010512A (en) | 2011-04-13 |
| CN102010512B true CN102010512B (en) | 2012-12-12 |
Family
ID=43840856
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CN2010105058496A Active CN102010512B (en) | 2010-10-12 | 2010-10-12 | Preparation method and application of water-soluble chitosan micro-particles |
Country Status (1)
| Country | Link |
|---|---|
| CN (1) | CN102010512B (en) |
Families Citing this family (4)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN102389398A (en) * | 2011-08-26 | 2012-03-28 | 广东药学院 | Chitosan-loaded capsaicin microspheres, preparation method thereof, and application thereof |
| CN102293752B (en) * | 2011-08-26 | 2013-01-23 | 广东药学院 | Preparation method of chitosan-carried capsaicin microsphere as well as microsphere and application of microsphere in weight reduction and sugar reduction |
| CN102728079A (en) * | 2012-06-21 | 2012-10-17 | 厦门蓝湾科技有限公司 | Drying method of water-soluble low molecular weight chitosan |
| US20140349960A1 (en) * | 2013-05-23 | 2014-11-27 | Taiwan Hopax Chems. Mfg. Co, Ltd. | Composition for body fat consumption |
Citations (2)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN101732259A (en) * | 2009-12-29 | 2010-06-16 | 广东药学院 | Chitosan micron particle as well as preparation method and application thereof |
| CN101732257A (en) * | 2009-12-29 | 2010-06-16 | 广东药学院 | Chitosan nanoparticle and preparation method and application thereof |
Family Cites Families (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| KR100592364B1 (en) * | 2004-08-17 | 2006-06-22 | 학교법인 성균관대학 | Gastrointestinal retention type porous hydrogel based on glycol-based chitosan derivatives |
-
2010
- 2010-10-12 CN CN2010105058496A patent/CN102010512B/en active Active
Patent Citations (2)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN101732259A (en) * | 2009-12-29 | 2010-06-16 | 广东药学院 | Chitosan micron particle as well as preparation method and application thereof |
| CN101732257A (en) * | 2009-12-29 | 2010-06-16 | 广东药学院 | Chitosan nanoparticle and preparation method and application thereof |
Non-Patent Citations (1)
| Title |
|---|
| 宋涛.壳聚糖以及衍生物对大鼠肥胖的治疗与预防作用研究.《中国优秀硕士学位论文全文数据库 医药卫生科技辑（2009年）》.2009,(第8期),摘要及正文第16-28页. * |
Also Published As
| Publication number | Publication date |
|---|---|
| CN102010512A (en) | 2011-04-13 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| Zeng et al. | Synthesis and antidiabetic properties of chitosan-stabilized selenium nanoparticles | |
| CN106580919B (en) | A kind of ganoderma lucidum spore oil microcapsule powder and its preparation method and application | |
| CN102010512B (en) | Preparation method and application of water-soluble chitosan micro-particles | |
| CN102215850B (en) | Composition containing fucoxanthin extract | |
| Li et al. | Improvement of fucoxanthin oral efficacy via vehicles based on gum Arabic, gelatin and alginate hydrogel: Delivery system for oral efficacy enhancement of functional food ingredients | |
| CN108175744A (en) | A kind of scutelloside microemulsion solution and scutelloside micro emulsion gels and its preparation method and application | |
| CN102885060A (en) | Avermectin nanometer microemulsion and preparation method thereof | |
| de Morais et al. | Nanoencapsulation of the bioactive compounds of Spirulina with a microalgal biopolymer coating | |
| CN105832675B (en) | A kind of load selenium chitosan microball of controllable sustained-release selenium anion and preparation method thereof | |
| CN103316031B (en) | Weight reduction and body fat reduction applications of chitosan oligosaccharide | |
| CN115364054A (en) | Colon-targeted oil-in-water Pickering emulsion based on shellac nanoparticles and chitosan, and preparation and application thereof | |
| CN101978954B (en) | Preparation and application of chitosan particles | |
| CN101732259B (en) | Chitosan micron particle as well as preparation method and application thereof | |
| CN101810577B (en) | Gossypol intravenous injection fatty emulsion for curing tumors | |
| CN103690580A (en) | Microemulsion extraction method and microemulsion extract of Andrographis paniculata | |
| CN109864244A (en) | A kind of method that aurantiin improves beta carotene liposome stability | |
| CN103006617B (en) | Decoquinate oral micro-capsule preparation and preparation process thereof | |
| CN109485740B (en) | Linoleic acid esterification resistant starch and preparation method and application thereof | |
| CN114948880B (en) | Preparation method of caffeic acid phenethyl ester nano stable slow release formulation | |
| CN102552137A (en) | Triptolide fat emulsion injection and preparation method thereof | |
| CN101912407A (en) | Weight-reducing and lipid-lowering composition | |
| CN110074392A (en) | A kind of Antialcoholic liver-protecting nourishing the stomach shield intestines composition and preparation method thereof | |
| CN109157549A (en) | EGCG G. lucidum spores Softgel and preparation method thereof | |
| CN107412181A (en) | A kind of preparation method of amphipathic Bletilla glucomannan skeleton control lipid nano particle release | |
| CN105106950B (en) | A kind of immunologic adjuvant of live vaccine, preparation method and applications |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| C06 | Publication | ||
| PB01 | Publication | ||
| C10 | Entry into substantive examination | ||
| SE01 | Entry into force of request for substantive examination | ||
| C14 | Grant of patent or utility model | ||
| GR01 | Patent grant | ||
| C56 | Change in the name or address of the patentee | ||
| CP01 | Change in the name or title of a patent holder |
Address after: 510006 Guangdong City, Guangzhou province outside the University of East Ring Road, No. 280 Patentee after: Guangdong Pharmaceutical University Address before: 510006 Guangdong City, Guangzhou province outside the University of East Ring Road, No. 280 Patentee before: Guangdong Pharmaceutical University |